Common pathogens
Antibiotic-resistant bacterial strains are strains for which there is a high probability of treatment failure regardless of the type of treatment and the dose of antibiotic used. Resistance breakpoints for various antibiotics for each bacterial species are defined annually by the Antibiogram Committee of the French Society of Microbiology (CA-SFM). However, different resistance breakpoints may be used to ensure data comparability with international standards (see Neisseria gonorrhoeae). For antifungals, the interpretation breakpoints used by the CNR are those defined by the CLSI (Clinical and Laboratory Standards Institute) (http://www.clsi.org/) pending those from the EUCAST committee.The table below summarizes the updated data available for the main bacterial species pathogenic to humans, for which resistance phenomena are of public health interest given the treatment failures they may cause.
Click on the name of the pathogen or antimicrobial to access more data.
| Pathogen |
Main indicator of resistance |
% in the species |
Year |
Geographic coverage |
Sources |
| BACTERIA | |||||
| erythromycin, ciprofloxacin |
864 |
2017 |
National |
- CNR Campylobacter and Helicobacter - Public Health France | |
| erythromycin, ciprofloxacin |
< 158 |
2017 |
National |
- CNR Campylobacter and Helicobacter - Public Health France | |
| glycopeptides, ampicillin/amoxicillin (I+R) |
< 1< 1 |
2017 |
National |
- Onerba - CNR-affiliated laboratory for enterococci - CNR for Antibiotic Resistance - Public Health France | |
| glycopeptides, ampicillin/amoxicillin (I+R) |
< 182 |
2017 |
national |
- Onerba - CNR-affiliated laboratory for enterococci - CNR on antibiotic resistance - Santé publique France | |
| 3rd-generation cephalosporins, fluoroquinolones, carbapenems |
10.3 15.1< 0.1 |
2017 |
national |
- Onerba - BMR-Raisin - Santé publique France | |
| amoxicillin |
21.0 |
2017 |
national |
- CNR Haemophilus influenzae - Public Health France | |
| 3rd-generation cephalosporins, carbapenems |
29.0 0.7 |
2017 |
national |
- Onerba - Public Health France | |
| multidrug resistance* |
1.7 |
2016 |
national |
- CNR Mycobacteria and Mycobacterial Resistance to Antituberculosis Drugs - Santé publique France | |
| ceftriaxone >0.125–0.25 mg/L >0.25 mg/L |
00 |
2016 |
National |
- National Reference Center for Gonococci - Public Health France | |
| penicillin G (I+R) rifampicin |
300 |
2017 |
National |
- Meningococcal National Reference Center - Public Health France | |
| ceftazidime carbapenems |
12,213,9 |
2017 |
national |
- Onerba - Public Health France | |
| third-generation cephalosporin (children) and ciprofloxacin (adults) |
< 1 0 |
2016 |
National |
- CNR for Salmonella - Public Health France | |
| third-generation cephalosporin (children) and ciprofloxacin (adults) |
3.5 0 |
2016 |
national |
- CNR for Salmonella - Public Health France | |
| Salmonella enterica serotype 1,4,[5],12:i:- (monophasic variant of S. Typhimurium) |
third-generation cephalosporin (children) and ciprofloxacin (adults) |
2.5 0 |
2016 |
national |
- CNR for Salmonella - Public Health France |
| ciprofloxacin azithromycin |
13.1 20.6 |
2017 |
national |
- CNR for Escherichia coli and Shigella - Santé publique France | |
| Methicillin |
12.9 (in healthcare settings) |
2017 |
national |
- Onerba - BMR-Raisin - CNR for Staphylococci - Santé publique France | |
| penicillin G (I+R) erythromycin (I+R) |
25,326,3 |
2016 Preliminary data |
national |
- National Reference Center for Pneumococci - Public Health France | |
| erythromycin Adult Child tetracycline |
3 3 113 |
2017 |
National |
- Streptococcus Reference Standards - Onerba - Public Health France | |
| YEAST | |||||
| fluconazole, voriconazole |
00 |
2017 |
regional |
- CNR Mycology and Antifungals | |
| fluconazole, voriconazole |
see fact sheet |
2017 |
Regional (Ile-de-France) |
- CNR Mycology and Antifungals | |
